PD-L1 mAb (10F.9G2) TM, InVivoPure+

Programmed death-1 (PD-1) is a cell surface receptor that functions as a T cell checkpoint and plays a central role in regulating T cell exhaustion. Binding of PD-1 to its ligand, programmed death-ligand 1 (PD-L1), activates downstream signaling pathways and inhibits T cell activation. Moreover abnormally high PD-L1 expression on tumor cells and antigen-presenting cells in the tumor microenvironment mediates tumor immune escape, and the development of anti-PD-1/PD-L1 antibodies has recently become a hot topic in cancer immunotherapy. The 10F.9G2 antibody is a monoclonal antibody specific for the mouse protein PD-L1 (Programmed Death Ligand 1), also known as B7-H1 or CD274. PD-L1 is a 40 kDa type I transmembrane protein that belongs to the B7 family of the immunoglobulin superfamily. It is expressed on T cells, B cells, NK cells, dendritic cells, as well as on IFN-γ stimulated monocytes, epithelial cells and endothelial cells. The interaction of PD-L1 with its receptor PD-1 on T cells leads to the inhibition of T cell proliferation and cytokine production. The anti-PD-L1 (10F.9G2) blocking antibody blocks interaction of PD-L1 with both of its binding partners, PD-1 and CD80 (B7-1) .